Kayyem Jon Faiz
Director at Inhibrx Biosciences, Inc. (INBX) and others. 6 filings on Aeon since Jan 6, 2026.
Alert me on this person−14.2%
Return per buy, 1 monthS&P +0.5%
That is −14.7 points vs the S&P
Record
Same numbers as the leaderboard, once there are 3 buys with a result3
Decisions
1
Companies
−14.2%
Return
+0.5%
S&P, same days
−14.7
vs S&P
0%
Up
None
After selling
Planned sales (Form 144) count toward nothing: not the record, not a decision, not a signal. A sale reported on a Form 4 is measured apart, in its own column. "After selling" is what the stock did after each sale against the S&P over the same days, sign flipped, so a positive number means the stock fell behind the market after the sale. Sales never count toward the record, a signal or a score.
Filings
on Aeon, newest first
One filing can name more than one person, so a filing can appear on more than one page. A filing marked "Planned sale" is a Form 144, which is notice of a sale the person means to make, not a trade, and it counts toward nothing here.
Loading the filings.